Neoadjuvant immunotherapy improves outcomes in high-risk melanoma patients.

Published Date: 02 Mar 2023

High-risk melanoma patients who received the drug pembrolizumab before or after surgery to remove the cancer had a higher risk of developing melanoma than those who did not have a similar condition that eliminated cancer cells.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study: Rapamycin slows the progression of cancer by reducing aging and concentrating on precancerous cells.

2.

Can Alternating Venetoclax Regimens Improve AML Outcomes?

3.

Cancer detection recovered following pandemic disruptions

4.

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

5.

Research identifies nearly 200 potential breast carcinogens in food packaging materials


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot